Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2023.1150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Bokyung Ahn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Neoplasm Invasiveness. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Science, ICT and Future Planning, Asan Institute for Life Sciences, Asan Medical Center.
Abstract (Originalsprache)
Purpose
In this study, we aimed to determine the clinicopathologic, radiologic, and molecular significance of the tumor invasiveness to further stratify the patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) who can be treated less aggressively. Materials and Methods Clinicopathologic and radiologic characteristics of 166 surgically resected HG UTUC (48 noninvasive, and 118 invasive) cases were evaluated. Six noninvasive UTUC cases with intratumoral tumor grade heterogeneity were selected for whole-exome sequencing (WES) to understand the underlying molecular pathophysiology. Barcode-tagging sequencing was done for validation of the target genes from WES data.
Results
Patients with noninvasive UTUC showed no cancer-specific death with better cancer-specific survival (p < 0.001) and recurrence-free survival (p < 0.001) compared to the patients with invasive UTUC. Compared to the invasive UTUC, noninvasive UTUC was correlated to a low grade (LG) on the preoperative abdominal computed tomography (CT) grading system (p < 0.001), histologic intratumoral tumor grade heterogeneity (p=0.018), discrepancy in preoperative urine cytology diagnosis (p=0.018), and absence of urothelial carcinoma in situ (p < 0.001). WES of the heterogeneous components showed mutually shared HRAS and FGFR3 mutations shared between the HG and LG components. HRAS mutation was associated with the lower grade on preoperative abdominal CT and intratumoral tumor grade heterogeneity (p=0.045 and p < 0.001, respectively), whereas FGFR3 mutation was correlated to the absence of carcinoma in situ (p < 0.001).ConclusionAccording to our comprehensive analysis, HG noninvasive UTUC can be preoperatively suspected based on distinct preoperative radiologic, cytologic, histologic, and molecular features. Noninvasive HG UTUC shows excellent prognosis and thus should be treated less aggressively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Medical Science, Biomedical Science, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Förderung
- Ministry of Science, ICT and Future Planning
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Ahn, B., Kim, D., Park, K. J., Park, J. M., Yoon, S. Y., Hong, B., Cho, Y. M., & Kim, D. (2024). Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.1150
Vancouver
Ahn B, Kim D, Park KJ, Park JM, Yoon SY, Hong B, et al. Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.1150
BibTeX
@article{Ahn2024,
author = {Ahn, Bokyung and Kim, Doeun and Park, Kye Jin and Park, Ja-Min and Yoon, Sun Young and Hong, Bumsik and Cho, Yong Mee and Kim, Deokhoon},
title = {Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2023.1150}
}
EUVIMED